Meglumine antimonate
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
NIAID ChemDB | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | Variable |
Molar mass | Variable |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
See also
References
- ↑ PMID 9455509 (PMID 9455509)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ Aventis press release, 15 April 2005. Template:De icon
Categories:
- Pages with script errors
- Pages with incomplete PMID references
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drug
- Antiprotozoal agents
- Antimony heterocycles